Advanced Enzyme Technologies Board Meeting Scheduled for May 9, 2026 to Consider Q4FY26 Results

2 min read     Updated on 02 May 2026, 08:51 PM
scanx
Reviewed by
Naman SScanX News Team
AI Summary

Advanced Enzyme Technologies Ltd. has scheduled a board meeting for May 9, 2026, to consider and approve the annual financial statements for the financial year ended March 31, 2026, along with the fourth quarter results. The board will also consider recommending a final dividend for FY2026 and potentially declaring an interim dividend for FY2027. The trading window for dealing in the company's securities will remain closed until May 11, 2026, as per the regulatory intimation.

powered bylight_fuzz_icon
39280907

*this image is generated using AI for illustrative purposes only.

advanced enzyme tech has scheduled a meeting of its Board of Directors for Saturday, May 9, 2026. The meeting will be held to consider and approve the Annual Financial Statements, both standalone and consolidated, for the financial year ended March 31, 2026, along with the results of the fourth quarter.

Agenda Items

The board will deliberate on several key matters during the meeting:

  • To consider and approve Annual Financial Statements (Standalone & Consolidated) for the financial year ended March 31, 2026 along with Q4 results
  • To consider and recommend Final dividend, if any, for the financial year ended March 31, 2026
  • To consider and declare Interim dividend, if any, for the financial year ended March 31, 2027

Trading Window Closure

In compliance with regulatory requirements, the company has informed that the Trading Window for dealing in the securities of the company will continue to remain closed up to May 11, 2026. This closure follows the earlier intimation dated March 26, 2026.

Company Details

Parameter Details
CIN L24200MH1989PLC051018
BSE Scrip Code 540025
NSE Trading Symbol ADVENZYMES
Registered Address Sun Magnetica, 'A' wing, 5th Floor, LIC Service Road, Louiswadi, Thane (W)-400 604, India

The intimation has been uploaded on the company's website at www.advancedenzymes.com and is also available on the websites of BSE Limited ( www.bseindia.com ) and National Stock Exchange of India Ltd. ( www.nseindia.com ).

Historical Stock Returns for Advanced Enzyme Tech

1 Day5 Days1 Month6 Months1 Year5 Years
+2.95%+16.23%+30.76%+12.47%+19.75%-14.18%

What factors could influence Advanced Enzyme Technologies' dividend policy decisions for both the final FY26 and interim FY27 dividends?

How might the company's Q4 FY26 results impact investor sentiment and stock performance when trading resumes on May 11, 2026?

What strategic initiatives or market expansions could Advanced Enzyme Technologies announce following their financial review?

Advanced Enzyme Technologies Limited Files SEBI Compliance Certificate for Q4FY26

1 min read     Updated on 10 Apr 2026, 03:23 PM
scanx
Reviewed by
Radhika SScanX News Team
AI Summary

Advanced Enzyme Technologies Limited submitted its mandatory SEBI compliance certificate for Q4FY26 under Regulation 74(5) of Depositories and Participants Regulations. The certificate, received from Registrar and Transfer Agents MUFG Intime India Private Limited, confirms proper dematerialisation processes for the quarter ended March 31, 2026. The submission demonstrates regulatory adherence for securities handling and depository participant operations.

powered bylight_fuzz_icon
37360384

*this image is generated using AI for illustrative purposes only.

Advanced enzyme tech has filed its quarterly compliance certificate under SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended March 31, 2026. The certificate submission demonstrates the company's adherence to mandatory regulatory requirements governing securities dematerialisation processes.

Regulatory Compliance Details

The certificate was submitted under Regulation 74(5) of the Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018. Company Secretary and Head-Legal Sanjay Basantani signed the submission letter dated April 10, 2026, forwarding the certificate to both BSE Limited and National Stock Exchange of India Limited.

Parameter: Details
Quarter Period: March 31, 2026
Regulation: SEBI Depositories Regulation 74(5)
Submission Date: April 10, 2026
Signatory: Sanjay Basantani, Company Secretary

Registrar and Transfer Agent Confirmation

MUFG Intime India Private Limited, formerly Link Intime India Private Limited, serves as the company's Registrar and Transfer Agents. The agency provided the confirmation certificate dated April 3, 2026, signed by Sr. Vice President-Corporate Registry Ashok Shetty.

The certificate confirms that securities received from depository participants for dematerialisation during the quarter were properly processed within prescribed timelines. MUFG Intime confirmed that all security certificates received for dematerialisation were appropriately verified, mutilated, and cancelled after due verification by depository participants.

Dematerialisation Process Compliance

The confirmation certificate validates several key compliance aspects:

  • Securities received for dematerialisation were confirmed or rejected to depositories within required timeframes
  • All securities comprised in certificates have been listed on stock exchanges where earlier issued securities are listed
  • Security certificates were properly mutilated and cancelled after verification
  • Depository names were substituted in the register of members as registered owners

This quarterly filing represents standard regulatory compliance for listed companies, ensuring proper handling of securities dematerialisation processes and maintaining transparency in depository participant operations.

Historical Stock Returns for Advanced Enzyme Tech

1 Day5 Days1 Month6 Months1 Year5 Years
+2.95%+16.23%+30.76%+12.47%+19.75%-14.18%

Will Advanced Enzyme Tech's consistent regulatory compliance improve its ESG ratings and attract more institutional investors?

How might SEBI's evolving depositories regulations impact Advanced Enzyme Tech's operational costs in upcoming quarters?

Could the company's strong compliance track record position it favorably for potential index inclusions or rating upgrades?

More News on Advanced Enzyme Tech

1 Year Returns:+19.75%